Cargando…
Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report
Cannabidiol (CBD) rich products are successfully used in some countries for treating symptoms associated with autism spectrum disorder (ASD). Yet, CBD provides insufficient intervention in some individuals, or for some characterizing symptoms of ASD, raising the need for improved compositions. The c...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649447/ https://www.ncbi.nlm.nih.gov/pubmed/36386202 http://dx.doi.org/10.3389/fphar.2022.979403 |
_version_ | 1784827798353870848 |
---|---|
author | Raz, Noa Heller, Iso Lombardi, Titti Marino, Giorgio Davidson, Elyad M. Eyal, Aharon M. |
author_facet | Raz, Noa Heller, Iso Lombardi, Titti Marino, Giorgio Davidson, Elyad M. Eyal, Aharon M. |
author_sort | Raz, Noa |
collection | PubMed |
description | Cannabidiol (CBD) rich products are successfully used in some countries for treating symptoms associated with autism spectrum disorder (ASD). Yet, CBD provides insufficient intervention in some individuals, or for some characterizing symptoms of ASD, raising the need for improved compositions. The current study presents a case wherein pure CBD was sufficient for treating ASD during childhood and early adolescence. However, it became insufficient during puberty accompanied by increased hyperactivity, agitation, and frequent severe aggressive behavior. Increasing the CBD dose did not result in significant improvement. Enriching the pure CBD with a carefully selected blend of anxiolytic and calming terpenes, resulted in gradual elimination of those aggressive events. Importantly, this was achieved with a significantly reduced CBD dose, being less than one-half the amount used when treating with pure CBD. This case demonstrates a strong improvement in efficacy due to terpene enrichment, where pure CBD was not sufficient. Combined with terpenes’ high safety index and the ease with which they can be incorporated into cannabinoid-containing products, terpene-enriched CBD products may provide a preferred approach for treating ASD and related conditions. The careful selection of terpenes to be added enables maximizing the efficacy and tailoring the composition to particular and changing needs of ASD subjects, e.g., at different times of the day (daytime vs nighttime products). |
format | Online Article Text |
id | pubmed-9649447 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96494472022-11-15 Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report Raz, Noa Heller, Iso Lombardi, Titti Marino, Giorgio Davidson, Elyad M. Eyal, Aharon M. Front Pharmacol Pharmacology Cannabidiol (CBD) rich products are successfully used in some countries for treating symptoms associated with autism spectrum disorder (ASD). Yet, CBD provides insufficient intervention in some individuals, or for some characterizing symptoms of ASD, raising the need for improved compositions. The current study presents a case wherein pure CBD was sufficient for treating ASD during childhood and early adolescence. However, it became insufficient during puberty accompanied by increased hyperactivity, agitation, and frequent severe aggressive behavior. Increasing the CBD dose did not result in significant improvement. Enriching the pure CBD with a carefully selected blend of anxiolytic and calming terpenes, resulted in gradual elimination of those aggressive events. Importantly, this was achieved with a significantly reduced CBD dose, being less than one-half the amount used when treating with pure CBD. This case demonstrates a strong improvement in efficacy due to terpene enrichment, where pure CBD was not sufficient. Combined with terpenes’ high safety index and the ease with which they can be incorporated into cannabinoid-containing products, terpene-enriched CBD products may provide a preferred approach for treating ASD and related conditions. The careful selection of terpenes to be added enables maximizing the efficacy and tailoring the composition to particular and changing needs of ASD subjects, e.g., at different times of the day (daytime vs nighttime products). Frontiers Media S.A. 2022-10-28 /pmc/articles/PMC9649447/ /pubmed/36386202 http://dx.doi.org/10.3389/fphar.2022.979403 Text en Copyright © 2022 Raz, Heller, Lombardi, Marino, Davidson and Eyal. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Raz, Noa Heller, Iso Lombardi, Titti Marino, Giorgio Davidson, Elyad M. Eyal, Aharon M. Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report |
title | Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report |
title_full | Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report |
title_fullStr | Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report |
title_full_unstemmed | Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report |
title_short | Terpene-Enriched CBD oil for treating autism-derived symptoms unresponsive to pure CBD: Case report |
title_sort | terpene-enriched cbd oil for treating autism-derived symptoms unresponsive to pure cbd: case report |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9649447/ https://www.ncbi.nlm.nih.gov/pubmed/36386202 http://dx.doi.org/10.3389/fphar.2022.979403 |
work_keys_str_mv | AT raznoa terpeneenrichedcbdoilfortreatingautismderivedsymptomsunresponsivetopurecbdcasereport AT helleriso terpeneenrichedcbdoilfortreatingautismderivedsymptomsunresponsivetopurecbdcasereport AT lombardititti terpeneenrichedcbdoilfortreatingautismderivedsymptomsunresponsivetopurecbdcasereport AT marinogiorgio terpeneenrichedcbdoilfortreatingautismderivedsymptomsunresponsivetopurecbdcasereport AT davidsonelyadm terpeneenrichedcbdoilfortreatingautismderivedsymptomsunresponsivetopurecbdcasereport AT eyalaharonm terpeneenrichedcbdoilfortreatingautismderivedsymptomsunresponsivetopurecbdcasereport |